507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors - Anna Olsson-Brown; Joseph Sacco; Mark Middleton; Kevin Harrington; Robert Coffin; Andrea Pirzkall; Praveen Bommareddy; Isla Leslie; Francesca Aroldi; Pablo Nenclares; Tze Chan; Imran Saleem; et al. (Journal for ImmunoTherapy of Cancer, 2021)